Aarkstore - The Chinese Pharmaceuticals Market to 2024

1. Category : Healthcare Aarkstore - The Chinese Pharmaceuticals Market to 2024

2. Aarkstore - The Chinese Pharmaceuticals Market to 2024

3. Summary The OTC drugs market in China was characterised by a late start, but fast growth, along with huge potential in comparison to that of the mature OTC markets in many western countries. Your company should be benefiting from this market access – and this is only the OTC market – what has the growth been throughout the whole Chinese pharma sector? This report will tell you.“China’s pharmaceutical” sales growth is based on economic growth in the country: This has resulted in increased healthcare expenditure internally, and increased manufacture and export. Increasing urbanisation, disposable income, aging population, health education, lifestyle diseases and government investments and initiatives for healthcare infrastructure improvement have helped the market growth considerably. Have you captured enough of the Chinese market?

4. Annually, an average of $190 is spent for the treatment of diabetes, per patient, in China. By 2030, in China, diabetes is expected to cost Yuan 173.4bn ($28 bn) a year. China is expected to top the world’s diabetes tables both in terms of sheer numbers and population prevalence. This is true across a range of complaints and products types – your company must capture a segment of this market TODAY.Anti-Counterfeiting and anti-corruption – How the Chinese market is changingCounterfeit drugs are successfully introduced in to the lengthy and complicated delivery chain because of the highly fragmented nature of the market. A lack of regular inspections by any recognised drug enforcement / regulatory bodies, again due to the highly fragmented nature of production, allows counterfeit / poor quality drugs into the Chinese pharma market. Moreover, wide spread corruption also helps the distribution of counterfeit drugs. What are the Chinese regulators, and the global manufacturers doing to change this? Find out in this unique report.

5. Table of Contents: Executive Summary 1.1. Chinese Pharmaceutical Market Review 1.2. Chapter Breakdown 1.3. Research and Analysis Methods 2. Drivers & Restraints of the Chinese Pharmaceutical Market 2.1 An Ageing Population will drive pharmaceutical market growth in China 2.2 Increase in Chinese urbanisation 2.3 Increase in Healthcare expenditure will increase drug demand in China 2.4 Government policies and changing environment for MNCs in China 2.5 Increased demand for improved drug quality

6. List Of Tables Table 2.1.1: Percentage of Chinese population aged 60 and over / 65 and over in 2000, 2011 & 2016 Table 2.1.2: Health spending in China, India and the US, 2009 & 2011 ($/p/a & percentage change) Table 2.1.3: Total Health Expenditure (as % of GDP); Selected Countries 2004 to 2011 Table 2.1.4: Life expectancy; Selected Countries 2004 to 2011 Table 2.2.1 Medical Coverage for Rural / Urban inhabitants in China 2006 / 2009 (million people) Table 2.2.2: Major cities in China by population (2011) Table 2.3.1 China’s Health Care Expenditure Per Capita 2003-2011 Table 2.6.1: Key New Drugs on the 2012 Essential Drugs List

7. List Of Figures Figure 2.1.1: China population growth trend 1950-2013Figure 2.1.2: Projected comparison of China’s population vs. other heavily populated countries 2016 (million people)Figure 2.1.3: China’s Age distribution: 2001 to 2011Figure 2.1.4: Life expectancy in ChinaFigure 2.2.1: China’s Rural and Urban population from 1990 to 2025 – Billion PeopleFigure 2.2.2: China’s Urbanisation Rate 1990-2025 (%)Figure 2.2.3: Per Capita Disposable Income Figure 2.3.1: China GDP growth trend (2004 – 2012)Figure 2.3.2: China’s total health expenditure (as % of GDP): 2004 to 2011Figure 2.3.3: China healthcare expenditure per capita growth trend (2003 – 2011)

8. Related Reports • Generic Drugs Market in Japan 2015-2019 • Lung Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Metastatic Brain Tumor-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Lupus Erythematosus-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Metastatic Breast Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

9. Related Reports • Malaria-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Metastatic Colorectal Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Melanoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 • Pharmaceuticals & Healthcare Market Research Reports

10. The Chinese Pharmaceuticals Market to 2024 Published: Sep 2014 | 160 Pages “China’s pharmaceutical” sales growth is based on economic growth in the country: This has resulted in increased healthcare expenditure internally, and increased manufacture and export.

11. Contact Us Office Office No. - 809, 8th Floor, B-Wing, Mahaavir Icon,  Plot No.- 89 & 90, Sector-15, CBD-Belapur, Navi Mumbai – 400614,  Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 You Can Visit : http://www.aarkstore.com OR Mail us at : contact@aarkstore.com Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news